Drug Target Review

NOVEMBER 29, 2023

Our primary focus is to design and develop RNA therapies for liver diseases. When combined with our in-house GMP-level RNA chemistry lab, Ochre Bio is able to progress from a new target to generating human data on a lead therapy in days. What does Ochre Bio do, can you give me an overview of your work?

Therapies 102

Therapies Disease RNA Engineering 102

Broad Institute

OCTOBER 16, 2024

William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines The groundbreaking, scalable technology is widely used in laboratories around the world today to efficiently produce large amounts of protein and RNA. Merkin (left) and F.

Vaccine 64

Vaccine RNA Laboratories Molecular Biology 64

Broad Institute

FEBRUARY 11, 2025

Mapping mRNA through its life cycle within a cell By Corie Lok February 11, 2025 Breadcrumb Home Mapping mRNA through its life cycle within a cell Xiao Wangs studies of how and where RNA is translated could lead to the development of better RNA therapeutics and vaccines.

RNA 52

RNA DNA Science Vaccine 52

Elrig

MARCH 10, 2025

Research & Innovation 2025 Keynote Speakers Announced Cambridge, UK, 24 January 2025: The European Laboratory Research & Innovation Group (ELRIG), a not-for-profit, volunteer-led organisation for the drug discovery community, today announced the keynote speakers for Research & Innovation 2025.

Research 52

Research Laboratories Medical Schools Engineering 52

keypoint

JANUARY 8, 2025

Our first Fellows Spotlight of 2025 goes to Keystone Symposia Fellow Dr. Abigael Cheruiyot! Studying RNA surveillance mechanisms, they identified nonsense mediated decay as a potential target for novel cancer therapies. She is very passionate about both science and promoting equity within the research community.

Medical Schools 59

Medical Schools RNA Laboratories Doctors 59

Drug Target Review

APRIL 1, 2025

In this interview, Williams shares the companys plans for 2025, the challenges of treating rare diseases, and how gene-silencing technology could unlock new treatment options. Vision for 2025: A major step towards clinical trials Since its founding, SynaptixBio has made significant progress in advancing its research and development efforts.

Disease 52

Disease Therapies Clinical Trials Cell Biology 52

Codon

FEBRUARY 19, 2025

ESM is a protein language model that captures certain aspects of protein structure and function, for example, but is blind to DNA or RNA-level features that drive cell behavior. Evo 2 was trained on DNA sequences but can make predictions about myriad aspects of biology, including RNA stability and protein structures. & McCarty N.

DNA 99

DNA Laboratories Engineering RNA 99